Iniparib
Advance Solid Tumors
SanofiSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Advance Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inv-8989 Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | CCC |
Carboplatin Sanofi | Phase 1 | CC |
Alk-N001 For Zhejiang Anglikang Pharmaceutical Co., Ltd. | Phase 1 | CC |
Kivu-107 Kivu Bioscience Inc. | Phase 1 | CC |
Same molecule, other indications
Iniparib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →